@article {W.A.:August 2000:1027-3719:758,
author = "W.A. Geerligs",
author = "R. van Altena",
author = "W.C.M. de Lange",
author = "D. van Soolingen",
author = "T.S. van der Werf",
title = "Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands",
journal = "The International Journal of Tuberculosis and Lung Disease",
volume = "4",
year = "August 2000",
abstract = "SETTING: Tuberculosis units (Beatrixoord, Haren; and Dekkerswald, Groesbeek) in the Netherlands.OBJECTIVE: To study the long-term treatment outcome of patients with multidrug-resistant tuberculosis (MDR-TB).DESIGN: Descriptive analysis of all consecutively admitted patients with MDR-TB between 1 January 1985 and 1 September 1998, with follow-up until 1 August 1999.RESULTS: Of 44 patients (31 male) enrolled in the study, 33 were foreign born and none were human immunodeficiency virus positive. At diagnosis 38 patients had sputum-smear positive pulmonary TB, and converted culture negative after a mean of 6 weeks, while six converted to negative later (mean 69 weeks). Most patients had micro-organisms resistant to several antimycobacterial drugs (mean = median: 5), including resistance to isoniazid and rifampin. In-patient treatment lasted a mean of 164 days (range 31–481), and patients were treated with six drugs on average. Side effects were common. Treatment lasted for a mean of 608 days (range 268–1626); five patients are still on treatment. Four patients were operated for TB, and two others were operated for post-TB sequelae. During the follow-up period six patients died, of whom three had active TB; 33 (75%) were considered cured.CONCLUSION: Mortality was only 14% after a mean follow-up period of 53 months. MDR-TB can be successfully treated, but requires much effort from both patients and carers, and the costs may be higher than is affordable in resource-poor countries.",
pages = "758-764(7)",
url = "http://www.ingentaconnect.com/content/iuatld/ijtld/2000/00000004/00000008/art00010"
}